SANTA CLARA, Calif. XenoPort, Inc. today announced positive results from a Phase 1 clinical trial of XP21279, a Transported Prodrug of levodopa, or L-Dopa.
55572
XenoPort announces positive results of a Phase 1 clinical trial of XP21279
123993
FDA approves new drug for multiple sclerosis
90632
Scientists discover potential drug delivery system
148133
GE Healthcare reports positive data for imaging agent
161739
New approach to treating high blood pressure
147662
Galenica's kidney drug meets endpoint in trial
32698
AstraZeneca and Daiichi Sankyo to co-promote Nexium
136378
Testequip expands into Solobox xenon test chambers
24642
Drug derived from the hydrangea root shows promise for autoimmune disorders
53455
AnaSpec introduces new HiLyte Fluor™ 405 fluorescent probe
59485
Consortium supports next generation drug discovery
46740
BioLineRx announces publication of pre-clinical results
26140
ClearKone® prescribed to more than 16,000 patients in 32 countries
52880
DLF Pramerica life revamps product portfolio
8416
NuPathe receives FDA approval for acute treatment of migraine
36993
Memory loss screening encouraged by maker of brain nutrition supplement Prevagen
88480
Mayo Clinic partnership to advance personalized medicine